History

Centaurus Consulting Group™, LLC was created in 2011 to support the pharmaceutical/biotech industry in achieving regulatory goals, specifically in the chemistry, manufacturing and controls (CMC) arena.

Mission

Enable our Clients to achieve regulatory approval under the “First time right” paradigm.

Core competencies include pharmaceutical development, CMC, regulatory and project management. In addition, Centaurus conducts confidential due diligences for the purpose of investment/divestment.

Leadership

Centaurus Consulting Group was founded in 2011 by Catherine Foulon, PhD.

Dr. Foulon completed her PhD in Nuclear Medicine at the University of Tours, France in 1991 and started an academic career in the United States (University of Pennsylvania, Harvard Medical School), culminating as an Associate Research Professor at Duke University Medical Center. Her projects focused on the development of radiopharmaceuticals for application in neuroscience and oncology and several leads qualified for clinical studies.

In 2000, Dr. Foulon transited into the biotech industry where tech transfers, combined to additional development work set the tone to the hands-on approach to CMC (Chemistry Manufacturing and Controls), Pre-clinical and Clinical activities. From there, Dr. Foulon achieved positions with increasing responsibilities, yielding to Project Lead as well as the authoring and reviewing of regulatory documents (INDs, IMPDs, Supplements, NDA/BLA/MAA and variations, DMF/ASMF, Clinical Protocols, Investigator’s Brochure and more).

The project management component, coupled to the “lead by example” paradigm prevail and Dr. Foulon’s managing style is reflected the “open book” policy whereby the strategy is vetted through the Team. Both the plan and the roadmap are clearly explained to the Stakeholders and the Team to enable a prompt execution.

View the full career profile of Dr. Foulon: